Dr Neil Chapman clinical lead hypertension and cardiovascular disease prevention (consultant physician, honorary senior lecturer, lead)
- 020 3313 7382
Adelle Ferguson Adom
Dr Neil Chapman is a consultant in general and cardiovascular medicine and clinical pharmacology at Imperial College Healthcare NHS Trust and honorary senior lecturer at Imperial College London. He qualified from the University of Cambridge before training in general medicine, clinical pharmacology and hypertension in London and at the University of Sydney, Australia.
Dr Chapman is a specialist in the management of hypertension (high blood pressure). He is a fellow of the British Hypertension Society and an accredited hypertension specialist of the European Society of Hypertension. He is lead clinician for the Peart-Rose clinic, a tertiary referral centre for hypertension and cardiovascular risk factor management at Hammersmith Hospital. His clinical and research interests include both primary and secondary cardiovascular disease prevention.
He sees outpatients with all aspects of hypertension, including confirmation and investigation of newly-diagnosed hypertension, ambulatory blood pressure monitoring, secondary hypertension, resistant and hard-to-control hypertension and patients who find it hard to tolerate usual treatments. He looks after inpatients with acute and general internal medical problems.
Hypertension, general and acute medicine, cardiovascular disease prevention
Research & publications
Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Blood Pressure Lowering Treatment Trialists' Collaboration. Ann Intern Med 2015;162:184-91. (Collaborator). doi:10.7326/M14-0773
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2015;385:867-74. (Collaborator). http://dx.doi.org/10.1016/S0140-6736(14)61171-5
Patel A, et al; Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015;22:920-30 (Chair, Clinical Endpoint Adjudication Committee). doi: 10.1177/2047487314530382
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. ADVANCE-ON Collaborative Group. N Engl J Med 2014;371:1392-406. (Local investigator). http://www.nejm.org/doi/full/10.1056/NEJMoa1407963
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2014;384:591-8. (Collaborator). http://dx.doi.org/10.1016/S0140-6736(14)61212-5
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. UMPIRE Collaborative Group. JAMA 2013;310:918-29. (Chair, International Clinical Endpoint Adjudication Committee). doi:10.1001/jama.2013.277064